Markowitz, JS; Zhu, H; Patrick, KS. Isopropylphenidate: An Ester Homolog of Methylphenidate with Sustained and Selective Dopaminergic Activity and Reduced Drug Interaction Liability J. Child Adol. Psychop., 18 Dec 2013, 23 (10), 648–654. 328 kB. https://doi.org/10.1089/cap.2013.0074
Luethi, D; Kaeser, PJ; Brandt, SD; Krähenbühl, S; Hoener, MC; Liechti, ME. Pharmacological profile of methylphenidate-based designer drugs Neuropharmacology, 15 May 2018, 134 (A), 133-140. 987 kB. https://doi.org/10.1016/j.neuropharm.2017.08.020
EMCDDA. New drugs in Europe, 2015, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 May 2016. 1.0 MB. #21
Luethi, D; Liechti, ME. Monoamine transporter and receptor interaction profiles in vitro predict reported human doses of novel psychoactive stimulants and psychedelics Int. J. Neuropsychoph., 1 Oct 2018, 21 (10), 926–931. 254 kB. https://doi.org/10.1093/ijnp/pyy047 #S1 Piperidines Isopropylphenidat
Carlier, J; Giorgetti, R; Varì, MR; Pirani, F; Ricci, G; Busardò, FP. Use of cognitive enhancers: methylphenidate and analogs Eur. Rev. Med. Pharmacol. Sci., 1 Jan 2019, 23 (1), 3–15. 676 kB. https://doi.org/10.26355/eurrev_201901_16741 #IPH
Hägele, JS; Basrak, M; Schmid, MG. Enantioselective separation of novel psychoactive substances using a Lux® AMP 3 μm column and HPLC-UV J. Pharm. Biomed. Anal., 5 Feb 2020, 179, 112967. 3.6 MB. https://doi.org/10.1016/j.jpba.2019.112967 #I3 LC